EP14.01-020 Trial in Progress: [177Lu]Lu-DOTA-TATE Combination Therapy in Treatment-Naïve Extensive Stage Small Cell Lung Cancer

New therapeutic agents are desperately needed for small cell lung cancer (SCLC), a high-grade, poorly differentiated neuroendocrine carcinoma of the lung, that often presents at an extensive stage (ES), and has high mortality rates. Response to current standard of care (SOC) is generally short-lived with most patients experiencing disease progression and a poor prognosis. Up to half of SCLC tumors express somatostatin receptors (SSTR). [177Lu]Lu-DOTA-TATE, a radioligand therapy, selectively targets SSTRs and has demonstrated a significant improvement in progression-free survival (PFS) and prolongation of overall survival (OS) in patients with SSTR-positive midgut neuroendocrine tumors.